Web Analytics

3 Latest Announced Rounds

  • $13,000,000
    Seed
    Hospital & Health Care
    Feb 4th, 2025
  • $2,000,000
    Seed

    2 Investors

    Biotechnology Research
    Feb 4th, 2025
  • $3,500,000
    Unknown

    2 Investors

    Software Development
    Feb 4th, 2025
$745.41M Raised in 48 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Vetigenics

start up
United States - Philadelphia, Pennsylvania
  • 04/02/2025
  • Seed
  • $6,000,000

At Vetigenics, we harness the power of the animal's own immune system to bring the latest advancements in biotechnology to improve pet health.
Vetigenics, founded by Nicola Mason BVetMD, PhD and Don Siegel PhD, MD both Professors at UPenn, have created the only comprehensive, canine single chain fragment variable (scFv) phage display libraries estimated to contain over 40 billion independent scFv members.

CANIBODIES™ are entirely canine scFvs uniquely selected from the library based on their antigen-binding capabilities, functionality and developability. As they are generated from native canine immunoglobulin germline genes, they do not require caninization or chimeric (mouse/canine) design and offer reduced immunogenicity when compared to antibodies generated by competitive methods.

Furthermore, as the library’s repertoire is not limited by central tolerance, CANIBODIES™ are highly versatile, can be rapidly, readily isolated and engineered into alternative therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs.

Working closely with a wide network of experts in animal and human health, Vetigenics is devoted advancing our portfolio of drug candidates to enhance and extend the lives of our cherished companions.

For more information contact:
Adriann Sax, CEO
asax@vetigenics.com


Related People

Adriann SaxFounder

Adriann Sax United States - New York City Metropolitan Area

Top performing, solutions-driven life sciences executive, entrepreneur and investor with experience leading organizations through start-up, change, revitalization, turnaround and accelerated growth. Personally credited with creating significant shareholder value for early-stage biotech to global top pharma through strategic leadership. Decisive and results-oriented with outstanding negotiation and crisis management skills. An engaging professional communicator with the ability to put others at ease, quickly building relationships based on mutual trust and benefit. Dynamic manager, mentor and advisor with strong cross-functional expertise and talent for building, cultivating and retaining internal talent and external partnerships.
* Strategy, Execution, Leadership
* Equity & Debt Capital
* Oncology R&D
* All Aspects of Drug Development & Commercialization
* Due Diligence, Deal Structuring & Negotiations
* Global Operations
* Business Development & Licensing
* Full P&L Responsibility
* Investor, Analyst and Board Relations